Drugs / Henagliflozein
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT04667143 | Jan 2021 → Sep 2022 | type 2 diabetes mellitus | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT06449833 | Jun 2024 → Nov 2026 expected | NAFLD1, type 2 diabetes mellitus | Zhujiang Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Henagliflozein | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06449833 ↗ |
| Action | Inhibit | “Henagliflozein-SGLT-2 inhibitor” NCT04667143 ↗ |